Overview

• Orforglipron, Eli Lilly’s once-daily oral GLP-1 therapy, demonstrated a 1.6% reduction in A1C and up to 7.9% body weight loss after 40 weeks in a Phase 3 trial.
• Unlike existing injectable GLP-1 drugs, orforglipron offers a needle-free alternative without dietary restrictions, potentially improving accessibility and adherence.
• Mild to moderate gastrointestinal side effects were reported, with an 8% discontinuation rate at the highest dose and no liver safety concerns observed.
• Over 65% of trial participants achieved A1C levels of 6.5% or lower, a key benchmark for diabetes management.
• Eli Lilly plans to seek FDA approval for orforglipron as a weight-loss treatment by late 2025 and as a diabetes therapy in 2026, with peer-reviewed publications and conference presentations expected mid-year.